类风湿关节炎患者中JAK激酶抑制剂与水痘带状疱疹病毒感染。文献系统评价
JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.
作者信息
Sánchez González Carmen Olga, Nieto González Juan Carlos
机构信息
Sección de Reumatología, Hospital Universitario del Sureste, Arganda del Rey, Madrid, Spain.
Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
出版信息
Reumatol Clin (Engl Ed). 2022 Oct;18(8):453-458. doi: 10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.
OBJECTIVES
JAK kinase inhibitors (JAKi) are a new therapeutic option in the treatment of rheumatoid arthritis, but they are not without risks, especially the incidence of herpes zoster (HZ).
MATERIAL AND METHODS
Systematic literature review that evaluates the incidence of HZ published in the clinical trials of the different JAK is marketed or under study.
RESULTS
The HZ rates ranged between 1.51 and 20.22. The results were expressed mainly as a percentage of events. The most recent studies better categorized the incidence of HZ and its severity.
CONCLUSION
JAK is are associated with an increased risk of HZ. Although the HZ rates of the selective JAK1 JAK is are lower, more studies are needed to confirm these results.
目的
JAK激酶抑制剂（JAKi）是治疗类风湿性关节炎的一种新的治疗选择，但它们并非没有风险，尤其是带状疱疹（HZ）的发病率。
材料与方法
系统文献综述，评估已上市或正在研究的不同JAK临床试验中发表的HZ发病率。
结果
HZ发病率在1.51至20.22之间。结果主要以事件百分比表示。最新研究对HZ的发病率及其严重程度进行了更好的分类。
结论
JAK与HZ风险增加有关。尽管选择性JAK1的HZ发病率较低，但需要更多研究来证实这些结果。
Zotero 插件